Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems

Bruker Corporation (Nasdaq: BRKR) today announced that it has acquired Spectral Instruments Imaging LLC, a leader in preclinical in-vivo optical imaging systems. This acquisition fills a gap in the technology and product portfolio of the Bruker BioSpin Preclinical Imaging (PCI) division, broadening its range of preclinical solutions for disease research.

Established in 2009 in Tucson, Spectral Instruments Imaging (SII) is at the forefront of technology for co-registered bioluminescence (BLI), fluorescence (FLI), and X-ray preclinical imaging. SII systems are engineered with advanced optics, patented illumination, -90C air-cooled high sensitivity cameras, absolute calibration for quantifiable imaging, excellent flexibility and ease of use.

The SII flagship system Lago X is designed for superior sensitivity and high-volume in-vivo imaging research. The SII high-efficiency AMI HTX system permits BLI, FLI and X-ray imaging with a benchtop system. SII Aura software provides a seamless workflow for enhanced productivity.

“Spectral Instruments Imaging systems perfectly complement the Bruker Preclinical offering,” said Keith Copeland, the CEO of SII. “Joining Bruker represents a significant milestone in our history, and we are looking forward to enabling our customers to benefit from different preclinical imaging modalities to understand biological disease processes even more comprehensively in vivo.”

Dr. Wulf-Ingo Jung, President of Bruker’s PCI division commented: “We are very pleased to welcome the talented SII team. Their advanced BLI, FLI and X-ray imaging systems complement our portfolio to better serve the diverse needs of our preclinical customers. We are committed to fostering strong collaborations with our customers for advanced preclinical in vivo disease research.”

Financial details of the transaction were not disclosed. In 2023, SII generated revenues of over $10 million and was profitable.

Fast and highest sensitivity SII Lago X in vivo imaging with capacity for 10 animals simultaneously (Photo: Business Wire)

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bruker BioSpin - NMR, EPR and Imaging. (2024, February 07). Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems. News-Medical. Retrieved on May 01, 2024 from https://www.news-medical.net/news/20240207/Bruker-Acquires-Spectral-Instruments-Imaging-the-Performance-Leader-in-Preclinical-In-Vivo-Optical-Imaging-Systems.aspx.

  • MLA

    Bruker BioSpin - NMR, EPR and Imaging. "Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems". News-Medical. 01 May 2024. <https://www.news-medical.net/news/20240207/Bruker-Acquires-Spectral-Instruments-Imaging-the-Performance-Leader-in-Preclinical-In-Vivo-Optical-Imaging-Systems.aspx>.

  • Chicago

    Bruker BioSpin - NMR, EPR and Imaging. "Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems". News-Medical. https://www.news-medical.net/news/20240207/Bruker-Acquires-Spectral-Instruments-Imaging-the-Performance-Leader-in-Preclinical-In-Vivo-Optical-Imaging-Systems.aspx. (accessed May 01, 2024).

  • Harvard

    Bruker BioSpin - NMR, EPR and Imaging. 2024. Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems. News-Medical, viewed 01 May 2024, https://www.news-medical.net/news/20240207/Bruker-Acquires-Spectral-Instruments-Imaging-the-Performance-Leader-in-Preclinical-In-Vivo-Optical-Imaging-Systems.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Investigating Food Fraud in the Honey Industry